SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is trending heavily as traders debate the impact of an unexpected public endorsement from President Trump following a significant recent sell-off. While the community is sharply divided between those calling for a short squeeze fueled by institutional accumulation and skeptics echoing Michael Burry's warnings about valuation and competition, the stock remains a major focus due to its critical role in defense-tech infrastructure.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is currently seeing intense retail and institutional interest as investors bet on its electro-optic polymer technology to solve data center bottlenecks in the AI infrastructure cycle. The community remains deeply divided, with bulls pointing to recent foundry integration partnerships and the potential for a major industry acquisition, while skeptics warn of pre-revenue risks and argue the current valuation is driven by speculative hype rather than fundamental milestones.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is surging following positive topline results from the Phase 2/3 OptimUM-02 trial, where the darovasertib-crizotinib combination significantly improved median progression-free survival in patients with first-line metastatic uveal melanoma. Investors and the biotech community are actively discussing this success as a major de-risking event that positions the company for an accelerated FDA filing and potential transition into a commercial-stage organization.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility and intense community debate as the token surges on rumors of high-profile integrations and its expansion into Web3 entertainment. While some traders are celebrating massive gains and pointing to upcoming global event partnerships as long-term catalysts, others remain deeply skeptical, frequently labeling the project a speculative pump-and-dump scheme.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is attracting significant investor attention as it progresses through multiple clinical catalysts, including upcoming trial updates for pancreatic and skin cancer. The community remains highly bullish, frequently pointing to strong institutional accumulation, a robust cash position without debt, and multiple analyst price target increases as reasons to accumulate shares before upcoming data readouts.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone is trending as investors weigh potential regulatory shifts impacting single-family home acquisitions alongside broader market anxiety regarding the liquidity of private credit vehicles. The community is actively debating the firm's significant exposure to AI-related infrastructure and its resilience against potential sector-wide deleveraging risks.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma Inc. is trending following contract awards from the U.S. government for quantum materials and high-speed datacom, signaling a potential shift toward commercialization that has sparked intense debate among investors. The community is sharply divided, with bulls pointing to the company's proprietary III-V-on-silicon platform and low-float potential, while vocal criticsciting lack of foundry partnerships and limited revenueare actively challenging the company's valuation and long-term viability.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors digest detailed Phase 3 data for Axpaxli, with clinical presentations at the Macula Society and investor webcasts fueling intense speculation regarding a potential regulatory path or acquisition. While the community is debating the clinical nuances of the trial results, sentiment is buoyed by heavy institutional interest and the stock's recovery from recent volatility as participants position themselves ahead of further updates.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing heavy volatility as traders react to the stock's role as a leveraged Bitcoin proxy amid broader market shifts and recent institutional inflows. The community remains deeply polarized, with active discussions focusing on the sustainability of Bitcoin treasury strategies versus dilution concerns, alongside high-stakes debates over price action and potential short-squeeze catalysts.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is seeing heightened attention following strong earnings results that highlighted robust performance in equities trading and investment banking. Market participants are actively discussing the bank's ability to navigate current market volatility, while debates continue regarding the broader financial sector's valuation and the impact of geopolitical and macroeconomic pressures on bank capital quality.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Elicio Therapeutics (NASDAQ:ELTX) Trading 1.6% Higher   - Here's What Happened

Elicio Therapeutics (NASDAQ:ELTX) Trading 1.6% Higher - Should You Buy...

Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?

Here is how Aura Biosciences, Inc. (AURA) and Elicio Therapeutics (ELTX) have performed compared to their sector so far this year.

Wall Street Analysts Predict a 42.28% Upside in Elicio Therapeutics (ELTX): Here's  What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in Elicio Therapeutics (ELTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year?

Here is how Quest Diagnostics (DGX) and Elicio Therapeutics (ELTX) have performed compared to their sector so far this year.

Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why

Elicio Therapeutics (ELTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. It focuses on its Amphiphile platform for trafficking lymph nodes. The company was founded by Darrell Irvine in August 2011 and is headquartered in Boston, MA.

ELTX
Elicio Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ELTX News

ELTXElicio Therapeutics Inc